Cytotherapy : Impact Factor & More
eISSN: 1477-2566pISSN: 1465-3249
Share this on:
Key Metrics
CiteScore 
8
Impact Factor
< 5
SNIP
1.01
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Cytotherapy
Cytotherapy Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
SJR
| Overview | |
| Publisher | ELSEVIER SCI LTD |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1999 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Cytotherapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Cytotherapy
Regenerative lung therapies: promise, mechanism and accountability.
- 21 Jun 2028
- Cytotherapy
High affinity CD16v/v allogeneic NK cell therapy, AB-101, enhances antibody-mediated cytotoxicity in B-cell driven diseases.
- 1 Sep 2026
- Cytotherapy
Quality control of biological raw materials to ensure the viral safety of cell and gene therapy products.
- 1 Sep 2026
- Cytotherapy
Platinum TALEN-mediated nonviral gene editing facilitates clinical-scale production of cancer antigen-reactive T cells.
- 1 Sep 2026
- Cytotherapy
Transient HA-100 exposure improves aggregate uniformity and cell-cell contact stability in suspension human pluripotent stem cell cultures.
- 1 Sep 2026
- Cytotherapy
Overcoming challenges in the implementation of chimeric antigen receptor (CAR) T-cell therapy in resource-constrained settings: Lessons from Brazil and India.
- 1 Sep 2026
- Cytotherapy
Regenerative lung therapies: promise, mechanism and accountability.
- 21 Jun 2028
- Cytotherapy
High affinity CD16v/v allogeneic NK cell therapy, AB-101, enhances antibody-mediated cytotoxicity in B-cell driven diseases.
- 1 Sep 2026
- Cytotherapy
Quality control of biological raw materials to ensure the viral safety of cell and gene therapy products.
- 1 Sep 2026
- Cytotherapy
Platinum TALEN-mediated nonviral gene editing facilitates clinical-scale production of cancer antigen-reactive T cells.
- 1 Sep 2026
- Cytotherapy
Transient HA-100 exposure improves aggregate uniformity and cell-cell contact stability in suspension human pluripotent stem cell cultures.
- 1 Sep 2026
- Cytotherapy
Overcoming challenges in the implementation of chimeric antigen receptor (CAR) T-cell therapy in resource-constrained settings: Lessons from Brazil and India.
- 1 Sep 2026
- Cytotherapy
FAQs on Cytotherapy
How long has Cytotherapy been actively publishing? 
What is the publishing frequency of Cytotherapy?
How many articles did Cytotherapy publish last year?
What is the eISSN & pISSN for Cytotherapy?
What is Citescore for Cytotherapy?
What is SNIP score for Cytotherapy?
Who is the publisher of Cytotherapy?
